EADV-Kongress 2025: GLP-1RA-Medikamente verringern das Sterbe- und Herz-Kreislauf-Risiko bei Psoriasis-Patienten drastisch – OTS.at

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.